Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 12/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529236 | 0.77 | SRC (0.44) | CSNK2A1PTGESEGFRERBB2SRC | |
| SCHEMBL29775134 | 0.77 | EGFR (0.46) | CSNK2A1PTGESEGFRERBB2SRC | |
| SCHEMBL4745808 | 0.77 | EGFR (0.43) | CSNK2A1PTGESEGFRERBB2SRC | |
| SCHEMBL13976998 | 0.77 | EGFR (0.46) | CSNK2A1PTGESEGFRERBB2SRC | |
| SCHEMBL27898582 | 0.73 | CSNK2A1 (0.49) | CSNK2A1PTGESHTTLMNACHEK1 | |
| SCHEMBL4745222 | 0.72 | SRC (0.55) | EGFRERBB2SRCGAK | |
| SCHEMBL15556832 | 0.71 | SLC22A12 (0.46) | CSNK2A1PTGESGAKHTTLMNA | |
| SCHEMBL28685487 | 0.70 | EGFR (0.41) | CSNK2A1PTGESEGFRERBB2SRC | |
| SCHEMBL4745277 | 0.69 | EGFR (0.38) | PTGESEGFRERBB2SRCGAK | |
| SCHEMBL4745279 | 0.69 | EGFR (0.38) | PTGESEGFRERBB2SRCGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | CSNK2A1 356/4885PTGES 3931/4885EGFR 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.